Early Diagnosis of Latent Tuberculosis Reactivation due to Drug Interaction between Cobicistat and Intranasal Fluticasone
Background. Single-tablet antiretroviral therapy is currently the first-line choice for the treatment of HIV infection. Some therapeutic regimens contain the CYP3A4 inhibitor cobicistat, which can interact with drugs undergoing hepatic first-pass metabolism, leading to unintended adverse effects. Ca...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Infectious Diseases |
| Online Access: | http://dx.doi.org/10.1155/2019/8243868 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849305481204465664 |
|---|---|
| author | Roberto Pineda-Reyes Alena Klochko |
| author_facet | Roberto Pineda-Reyes Alena Klochko |
| author_sort | Roberto Pineda-Reyes |
| collection | DOAJ |
| description | Background. Single-tablet antiretroviral therapy is currently the first-line choice for the treatment of HIV infection. Some therapeutic regimens contain the CYP3A4 inhibitor cobicistat, which can interact with drugs undergoing hepatic first-pass metabolism, leading to unintended adverse effects. Case Presentation. A 41-year-old man presented to the HIV clinic following a visit to the Emergency Department. His CD4+ count was 1,271 cells/μL, and viral load was undetectable in the previous month. The patient was on an antiretroviral therapy regimen containing cobicistat. He reported using a self-initiated over-the-counter fluticasone nasal spray for at least 2 weeks prior. He had a history of positive tuberculin skin test and a negative chest X-ray within the past year. He denied cough and was in no respiratory distress. A chest CT scan revealed a new thick-walled cavitary nodule in the right upper lobe. A CT-guided biopsy of the lesion yielded Mycobacterium tuberculosis. Conclusions. HIV-infected individuals have higher risk for tuberculosis reactivation regardless of their CD4+ count. Fluticasone’s hepatic metabolism is bypassed in the presence of CYP3A4 inhibitors, which increases its systemic bioavailability and the risk for impaired immunity. The goal of this report is to increase awareness among physicians about the potential adverse outcomes from the interaction of these drugs. |
| format | Article |
| id | doaj-art-0a4e1f386fbf4251a8d03b1cd48770b1 |
| institution | Kabale University |
| issn | 2090-6625 2090-6633 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Infectious Diseases |
| spelling | doaj-art-0a4e1f386fbf4251a8d03b1cd48770b12025-08-20T03:55:27ZengWileyCase Reports in Infectious Diseases2090-66252090-66332019-01-01201910.1155/2019/82438688243868Early Diagnosis of Latent Tuberculosis Reactivation due to Drug Interaction between Cobicistat and Intranasal FluticasoneRoberto Pineda-Reyes0Alena Klochko1Department of Internal Medicine, University of Central Florida College of Medicine, Orlando, FL, USADepartment of Internal Medicine, University of Central Florida College of Medicine, Orlando, FL, USABackground. Single-tablet antiretroviral therapy is currently the first-line choice for the treatment of HIV infection. Some therapeutic regimens contain the CYP3A4 inhibitor cobicistat, which can interact with drugs undergoing hepatic first-pass metabolism, leading to unintended adverse effects. Case Presentation. A 41-year-old man presented to the HIV clinic following a visit to the Emergency Department. His CD4+ count was 1,271 cells/μL, and viral load was undetectable in the previous month. The patient was on an antiretroviral therapy regimen containing cobicistat. He reported using a self-initiated over-the-counter fluticasone nasal spray for at least 2 weeks prior. He had a history of positive tuberculin skin test and a negative chest X-ray within the past year. He denied cough and was in no respiratory distress. A chest CT scan revealed a new thick-walled cavitary nodule in the right upper lobe. A CT-guided biopsy of the lesion yielded Mycobacterium tuberculosis. Conclusions. HIV-infected individuals have higher risk for tuberculosis reactivation regardless of their CD4+ count. Fluticasone’s hepatic metabolism is bypassed in the presence of CYP3A4 inhibitors, which increases its systemic bioavailability and the risk for impaired immunity. The goal of this report is to increase awareness among physicians about the potential adverse outcomes from the interaction of these drugs.http://dx.doi.org/10.1155/2019/8243868 |
| spellingShingle | Roberto Pineda-Reyes Alena Klochko Early Diagnosis of Latent Tuberculosis Reactivation due to Drug Interaction between Cobicistat and Intranasal Fluticasone Case Reports in Infectious Diseases |
| title | Early Diagnosis of Latent Tuberculosis Reactivation due to Drug Interaction between Cobicistat and Intranasal Fluticasone |
| title_full | Early Diagnosis of Latent Tuberculosis Reactivation due to Drug Interaction between Cobicistat and Intranasal Fluticasone |
| title_fullStr | Early Diagnosis of Latent Tuberculosis Reactivation due to Drug Interaction between Cobicistat and Intranasal Fluticasone |
| title_full_unstemmed | Early Diagnosis of Latent Tuberculosis Reactivation due to Drug Interaction between Cobicistat and Intranasal Fluticasone |
| title_short | Early Diagnosis of Latent Tuberculosis Reactivation due to Drug Interaction between Cobicistat and Intranasal Fluticasone |
| title_sort | early diagnosis of latent tuberculosis reactivation due to drug interaction between cobicistat and intranasal fluticasone |
| url | http://dx.doi.org/10.1155/2019/8243868 |
| work_keys_str_mv | AT robertopinedareyes earlydiagnosisoflatenttuberculosisreactivationduetodruginteractionbetweencobicistatandintranasalfluticasone AT alenaklochko earlydiagnosisoflatenttuberculosisreactivationduetodruginteractionbetweencobicistatandintranasalfluticasone |